Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature

BACKGROUND: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients does not recur and might thus be overtreated...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Knauer, M, Cardoso, F, Wesseling, J, Bedard, P L, Linn, S C, Rutgers, E J T, van 't Veer, L J
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3008599/
https://ncbi.nlm.nih.gov/pubmed/21081926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605916
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares